Understanding the role of phenotypic switching in cancer drug resistance by Gunnarsson, Einar Bjarki et al.
Understanding the role of phenotypic switching
in cancer drug resistance
Einar Bjarki Gunnarsson1,∗ Subhajyoti De2 Kevin Leder1 Jasmine Foo3,∗
1Department of Industrial and Systems Engineering, University of Minnesota, Twin Cities, MN 55455, USA.
2Center for Systems and Computational Biology, Rutgers Cancer Institute of New Jersey, NJ 08903, USA.
3School of Mathematics, University of Minnesota, Twin Cities, MN 55455, USA.
∗Corresponding authors: jyfoo@umn.edu (Jasmine Foo), gunna042@umn.edu (Einar Bjarki Gunnarsson).
Abstract
The emergence of acquired drug resistance in cancer represents a major barrier to treatment
success. While research has traditionally focused on genetic sources of resistance, recent findings
suggest that cancer cells can acquire transient resistant phenotypes via epigenetic modifications
and other non-genetic mechanisms. Although these resistant phenotypes are eventually relin-
quished by individual cells, they can temporarily ’save’ the tumor from extinction and enable
the emergence of more permanent resistance mechanisms. These observations have generated
interest in the potential of epigenetic therapies for long-term tumor control or eradication. In
this work, we develop a mathematical model to study how phenotypic switching at the single-cell
level affects resistance evolution in cancer. We highlight unique features of non-genetic resis-
tance, probe the evolutionary consequences of epigenetic drugs and explore potential therapeutic
strategies. We find that even short-term epigenetic modifications and stochastic fluctuations in
gene expression can drive long-term drug resistance in the absence of any bona fide resistance
mechanisms. We also find that an epigenetic drug that slightly perturbs the average retention of
the resistant phenotype can turn guaranteed treatment failure into guaranteed success. Lastly,
we find that combining an epigenetic drug with an anti-cancer agent can significantly outper-
form monotherapy, and that treatment outcome is heavily affected by drug sequencing.
Keywords: Mathematical modeling, cancer drug resistance, evolutionary dynamics, phenotypic
switching, epigenetics.
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1 Introduction
While cancer has traditionally been considered a genetic disease driven by Darwinian evolution at
the somatic level, it is now increasingly recognized that non-genetic sources of phenotypic varia-
tion may play an important role in tumor initiation, tumor progression and the evolution of drug
resistance [1, 2, 3, 4, 5, 6, 7, 8]. Common sources of non-genetic heterogeneity include DNA methy-
lation, histone modifications and other epigenetic mechanisms that alter gene expression, without
changing the genetic code, by controlling DNA accessibility during transcription, replication and
repair [9]. Since these mechanisms frequently operate at a significantly faster rate than genetic
mutations, they can serve as a substrate for natural selection and permanently influence tumor
evolution in the absence of any genetic events [1, 2, 6]. Another common source of variation in
gene expression is the inherent stochasticity of intracellular biochemical reactions, which includes
transcriptional noise. This stochasticity may give rise to heritable expression levels, albeit on the
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short time scale of one to a few cell divisions, whereas retention of epigenetic modifications has been
estimated on the order of 10-105 cell divisions [10, 11, 12]. As we will find, even such short-term
phenotypic states can dramatically impact the course of tumor evolution.
Here, we are primarily interested in the role of non-genetic mechanisms in conferring acquired
resistance to anti-cancer treatment, as has been explored in several recent experimental works.
In Sharma et al. [13], for example, the authors investigate the acute response of several cancer
cell lines1 to targeted anti-cancer agents, and they consistently observe the emergence of a drug-
tolerant phenotype (DTP) that is ‘transiently acquired and relinquished by individual cells within
the population at a low frequency’. The authors draw an analogy between DTP’s and slowly-
proliferating antibiotic-tolerant ‘persisters’ commonly observed in microbial populations [13, 14, 15],
whose survival within a more rapidly proliferating population represents an evolutionary means of
’bet-hedging’ against potential environmental stresses [16, 17, 18, 19]. Liau et al. [20] and Roesch
et al. [21, 22] similarly describe slow-cycling DTP’s in glioblastoma and melanoma, respectively,
and Knoechel et al. [23] identify a reversible drug-tolerant state in leukemia which appears to be
epigenetically mediated. For even further examples of experimental studies describing (often stem-
like) non-genetic phenotypces associated with tumorigenic potential or drug resistance in cancer,
we refer to e.g. [24, 25, 26, 27, 28], as well as recent reviews by Reyes and Lahav [29] and Salgia
and Kulkarni [30]. We now turn our attention to such studies that also incorporate a modeling
component.
In Gupta et al. [31], the authors employ a mathematical model of stochastic switching between
three cell types to infer the rates at which breast cancer cells transition between a selectively re-
sistant stem-like state and two non-stem-like states. Su et al. [32] show that phenotypic switching
between a drug-sensitive and drug-resistant state in melanoma is well-captured by a similar model,
and their study reveals the critical role played by drug-induced adoption of the resistant state,
relative to selection of preexisting cells in this state. Goldman et al. [33] further provide evidence of
chemotherapy-induced switching to a resistant CD44HiCD24Hi expression status in breast cancer,
and Pisco et al. [34] show that vincristine resistance in leukemia, mediated by overexpression of
the multidrug resistance protein 1 (MDR1), is primarily due to therapy-accelerated adoption of the
overexpressed state. Thus, while reversible drug-tolerant cells may arise naturally in drug-na¨ıve
cell populations, their emergence can also be directly influenced by anti-cancer treatment. Further
complicating the picture, Craig et al. [35] have hypothesized that genotypically and phenotypi-
cally distinct cells can cooperate to induce the adoption of drug tolerance, although the potential
mechanism behind such cooperation remains unclear.
Whereas transiently resistant cells serve the immediate function of protecting the tumor popu-
lation from extinction, their ultimate role appears to be to set the stage for the evolution of more
permanent resistance mechanisms, both of the genetic and epigenetic kind. In Sharma et al. [13], for
example, the authors report that during prolonged exposure of EGFR-mutant non-small cell lung
cancer (PC9) to erlotinib, a fraction of drug-tolerant cells become capable of proliferating normally
in drug, and that this more aggressive phenotype reverts less readily to sensitivity once removed
from drug. During even more prolonged exposure, Ramirez et al. [36] find that PC9 persister cells
give rise to diverse genetic resistance mechanisms, including de novo adoption of the EGFRT790M
gatekeeper mutation commonly observed in the clinic (see also Hata et al. [37]). Shaffer et al. [38]
report findings conceptually similar to Sharma et al. for melanoma cells treated with vemurafenib,
and they further report that prolonged drug exposure induces epigenetic reprogramming of the
drug-tolerant state, ultimately leading to a stable drug-resistant phenotype.
The above studies indicate that tumor cells in a wide variety of cancer types have the ability
to adopt reversible drug-resistant phenotypes, which can in turn facilitate the eventual acquisition
1Non-small cell lung cancer, melanoma, colorectal cancer, breast cancer and gastric cancer.
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Figure 1: Graphical representation of the model. Type-0 (drug-sensitive) cells transition to
type-1 (transiently resistant) cells at rate µ and type-1 cells transition back at rate ν. Each
phenotype has distinct growth characteristics, with r0 and r1 denoting the rates of cell division and
d0 and d1 denoting the rates of cell death. In the presence of an anti-cancer agent, the transiently
resistant type-1 phenotype undergoes epigenetic reprogramming to stable drug resistance at rate
η. Additionally, each cell type can acquire a resistance-conferring mutation at rate ξ0 and ξ1 per
cell division, respectively, on and off drug. Stably resistant (type-2) cells divide at rate r2 and die
at rate d2.
of bona fide resistance mechanisms. Such phenotypes can both preexist anti-cancer treatment and
be specifically induced or accelerated by therapy. The relatively fast rate at which non-genetic
phenotypes can be adopted, as compared to resistance-conferring mutations, poses a major chal-
lenge for clinical strategies. A deeper understanding of these dynamics is crucial to furthering our
understanding of cancer and to informing novel therapeutic efforts. Here, we develop a mathe-
matical model to investigate the evolutionary dynamics of a cell population that is able to employ
transiently resistant states as a survival strategy. Our goal is to gain quantitative insights into
resistance evolution in this setting, to highlight some of its unique characteristics, and to discuss
how an understanding of these dynamics can inform the design of treatment strategies.
2 Model description
We consider a multi-type branching process model [39], in which cells switch stochastically between
two distinct phenotypes, the drug-sensitive type-0 phenotype and the drug-resistant type-1 pheno-
type. A type-0 cell divides into two type-0 cells at (Poisson) rate r0, it dies at rate d0 and adopts
the type-1 phenotype at rate µ > 0, with λ0 := r0− d0 the net birth rate.2 A type-1 cell divides at
rate r1, dies at rate d1 and reverts to type-0 at rate ν > 0, with λ1 := r1−d1 the net birth rate (Fig
1). To capture the drug-sensitivity of type-0 cells and drug-resistance of type-1 cells, we assume
that λ0 < 0 and λ1 > 0 in the presence of an anti-cancer agent. Although this model assumes that
switching between phenotypes can occur at any time during the cell cycle, it can easily be adjusted
to allow switching to only occur at cell divisions (Appendix E).
These general two-type switching dynamics enable description of a variety of sources of phe-
notypic heterogeneity; for example, short-term drug-tolerant states conferred by transcriptional
noise can be captured by a large reversion rate ν, while longer-term states induced by epigenetic
phenomena are captured by a smaller ν. We also note that the switching rates µ and ν are in
general distinct, since the mechanism underlying phenotypic switching is in general asymmetric. A
simple example is DNA methylation/demethylation, where de novo methylation is carried out by
the DNA methyltransferases DNMT3a and DNMT3b, while demethylation usually occurs due to
a failure of the maintenance methyltransferase DNMT1 to faithfully preserve methylation patterns
during cell division [40]. In what follows, we will usually refer to the transition from type-0 to
2This means that each type-0 cell waits an exponential amount of time with rate a0 := r0+d0+µ (i.e. the waiting
time is exponentially distributed with mean 1/a0) before it either divides with probability r0/a0, dies with probability
d0/a0, or adopts the type-1 phenotype with probability µ/a0.
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type-1 as an epimutation and the transition back as a reversion, while keeping more general sources
of non-genetic variation (e.g. transcriptional noise) in mind.
To capture the evolution of more permanent resistance mechanisms, we assume that under anti-
cancer treatment, the type-1 phenotype undergoes epigenetic reprogramming to a stably resistant
phenotype at rate η. Alternatively, type-0 and type-1 cells can acquire a resistance-conferring
mutation at rate ξ0 and ξ1 per cell division, respectively (i.e. the mutation rate per time unit is r0ξ0
for type-0 cells and r1ξ1 for type-1 cells), both in the presence and absence of the anti-cancer agent
(Fig 1). Stably resistant (type-2) cells divide at rate r2 and die at rate d2, with λ2 := r2 − d2 > 0
the net birth rate. We assume throughout that no type-2 cell is present at detection, focusing on
how acquired resistance develops during anti-cancer treatment.
We note that the model outlined above assumes that epigenetic reprogramming from type-1
to type-2 occurs in a single stochastic event. Single-stage reprogramming is consistent e.g. with
a model of epigenetic gene silencing under recruitment of chromatin regulators suggested in a
recent paper by Bintu et al. [41], and with Brown et al.’s [6] notion of ’epigenetically poised’ states
that evolve to fixed acquired-resistant states via DNA methylation. Conversely, a multi-stage (or
more continuous) model appears more consistent e.g. with the findings of Sharma et al. [13] and
Shaffer et al. [38] described above, although the data in these works are insufficient to infer an
exact model. The distinction between single-stage and multi-stage reprogramming will not be
important to much of our investigation, since in Sections 4.1 and 4.2, we focus on behavior in the
absence of permanent resistance mechanisms (η = 0 and ξ0 = ξ1 = 0). In Sections 4.3 and 4.4, we
work with the minimal single-stage model, as this allows us to gain theoretical insights into the role
played by transiently resistant phenotypes in facilitating the evolution of more permanent resistance
mechanisms in the simplest possible setting, in terms of a single reprogramming parameter η. Our
results in these sections will still be meaningful for the multi-stage case if we interpret the type-
2 phenotype more generally as a stabler and more aggressive form of epigenetic resistance, not
necessarily representing a permanent acquired-resistant state. Moreover, once multi-stage models
are better understood mechanistically and quantitatively, our analysis can be easily extended to
capture these more complex dynamics, using the same multi-type branching process framework as
employed below.
2.1 Parametrization
For demonstration purposes, we adopt a baseline parameter regime chosen to mimic in vitro be-
havior of EGFR-mutant non-small cell lung cancer (PC9) reported by Sharma et al. [13] and Hata
et al. [37]. We estimate the birth and death rates of all phenotypes and the epimutation rate µ
using these works, but refer to other works for estimation of the reversion rate ν and the rates η, ξ0
and ξ1 of stable resistance acquisition. Details are provided in Appendix A. The exact parameter
values are not important to our investigation, but rather the qualitative setting encoded in the
regime: Type-0 cells proliferate rapidly in the absence of an anti-cancer agent and die rapidly in its
presence, while type-1 cells are able to maintain slow net proliferation under the anti-cancer agent.
Epigenetic reprogramming is further assumed to occur at a faster rate than resistance-conferring
mutations. To ensure that our main insights are not particular to our chosen regime, but that they
apply more generally across cancer cell populations capable of adopting slow-cycling, transiently
resistant phenotypes, we will usually examine a range of possible switching dynamics. We fur-
thermore discuss the sensitivity of our results to main model parameters, and perform robustness
analysis where appropriate. We finally note that the rapid in vitro dynamics that underlie Figures
2 to 6 can be translated into slower in vivo dynamics through appropriate rescaling of time, as is
discussed in Section 4.
4
3 Mean behavior and survival probability
We begin by deriving expressions for the average number of type-0 and type-1 cells alive at any
time t, assuming the absence of permanent resistance mechanisms (i.e. η = 0 and ξ0 = ξ1 = 0).
These expressions will be useful both for analyzing long-term tumor evolution and for estimating
the time at which permanent resistance first arises (Section 4.4).
Assume that the tumor consists of n type-0 cells and m type-1 cells at the start of anti-cancer
treatment. We will both be interested in the case m = 0, where resistance is mediated by drug-
induced adoption of the type-1 phenotype, and m  0, where transiently resistant cells preexist
treatment (in significant numbers). The switching dynamics of tumor cells are encoded in the
infinitesimal generator for the process,
A =
[
λ0 − µ µ
ν λ1 − ν
]
, (1)
where λ0 − µ (resp. λ1 − ν) is the net rate at which a type-0 (type-1) cell produces another type-0
cell, and µ (resp. ν) is the transition rate from type-0 to type-1 (type-1 to type-0). If we let φ0(t)
(resp. φ1(t)) denote the mean number of type-0 (type-1) cells alive at time t, we can calculate these
means as
[φ0(t) φ1(t)] = [n m] exp(At), (2)
which allows use to derive the following expressions:
φ0(t) =
nδ +m
δ + γ
eσt +
nγ −m
δ + γ
eρt,
φ1(t) =
γ(nδ +m)
δ + γ
eσt − δ(nγ −m)
δ + γ
eρt.
(3)
Details of the derivation are provided in Appendix B. The rate constants σ and ρ, with σ > ρ, are
the (real) eigenvalues of the infinitesimal generator A, given by
(λ0 − µ) + (λ1 − ν)±
√
((λ0 − µ)− (λ1 − ν))2 + 4µν
2
. (4)
In addition,
γ := (σ − (λ0 − µ))/ν > 0 (5)
is the long-run ratio between type-1 and type-0 cells in the tumor population, and
δ := ((λ0 − µ)− ρ)/ν > 0 (6)
is the long-run ratio between the size of a clone derived from a single type-0 vs. a single type-1 cell.
Note that the mean behavior of the process can either be expressed as a function of the fundamental
constants λ0, λ1, µ and ν, which capture single-cell level dynamics, or as a function of the derived
quantities γ, δ, σ and ρ, which capture long-run population-level behavior and may be more easily
observable in an experimental setting. Also note that the above expressions only depend on the
birth and death rates of each cell type through their net birth rates λ0 = r0− d0 and λ1 = r1− d1.
As expression (3) indicates, the long-run behavior of the tumor population is determined by
the sign of the rate constant σ. The population survives with positive probability if and only if
σ > 0, in which case it is said to be supercritical, while extinction is guaranteed for σ < 0, in
which case it is subcritical (see e.g. [39] for further information). For a supercritical population, the
survival probability can be computed by solving a system of two nonlinear equations, as is outlined
in Appendix C.
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4 Results
4.1 Resistance driven solely by phenotypic switching
We begin by investigating whether phenotypic switching can drive long-term resistance to contin-
uous anti-cancer treatment, even in the absence of permanent resistance mechanisms (i.e. η = 0
and ξ0 = ξ1 = 0). By examining when σ > 0, we can show that tumor survival is possible (i.e. the
tumor cell population is supercritical) if and only if
νλ0 + µλ1 > λ0λ1 (7)
(see Appendix D for details). By rewriting this condition as (recall that λ0 < 0 under anti-cancer
therapy)
ν/λ1 − µ/|λ0| < 1, (8)
we see that the rates ν/λ1 and µ/|λ0| of phenotypic switching, relative to net growth (or net decay)
of each phenotype, determine whether the tumor can persist under therapy. It is furthermore easy
to see that a sufficient condition for (8) is
ν/λ1 ≤ 1 i.e. 1/ν ≥ 1/λ1, (9)
which can be interpreted as a simple condition on the time scale of ’phenotypic memory’: The
tumor population has a chance of surviving treatment whenever the average memory 1/ν of the
resistant state equals or exceeds 1/λ1.
If we assume that the growth characteristics of type-0 and type-1 cells (λ0 and λ1) are fixed,
the condition (8) for supercriticality can be viewed as describing the region in the (µ, ν) plane that
lies below the ’critical line’
ν = λ1/|λ0| · µ+ λ1. (10)
Since µ and ν are small, and they may differ by orders of magnitude, it is more instructive to
visualize their relationship on a logarithmic scale. In Figure 2a, we show this log-scale ’critical
curve’ for two cases: (i) λ1  |λ0|, i.e. type-0 cells die rapidly and type-1 cells proliferate slowly
under anti-cancer treatment, as in our baseline parameter regime, and (ii) λ1 ∼ |λ0|, i.e. the type-1
net birth rate is of the same order as the type-0 net death rate. In both cases, the tumor population
is supercritical for ν ≤ λ1 (region A), which is our sufficient condition from (9), but the population
can still be supercritical for ν > λ1 (region B for λ1  |λ0| and regions B+C for λ1 ∼ |λ0|), the
degree to which is controlled by the slope λ1/|λ0| in (10).
We conclude from the above that phenotypic switching can in fact drive long-term drug resis-
tance in the absence of more permanent resistance mechanisms, and we identify two qualitatively
distinct evolutionary pathways to such resistance:
1. ν ≤ λ1: Population survival is driven by sufficiently long retention of the resistant phenotype,
independently of the rate of epimutation (µ) and type-0 sensitivity to the anti-cancer agent
(λ0).
2. ν > λ1 and µ > λ0(1−ν/λ1): Type-1 cells lose the resistant phenotype too quickly to sustain
the tumor by themselves, but this loss is compensated by sufficiently fast adoption of the
resistant state.
6
10-6 10-5 10-4 10-3 10-2
10-4
10-3
10-2
10-1 0 20 40 60 80 100
106
108
100
102
104
0 20 40 60 80 100
106
108
100
102
104
Figure 2: (a) Graphical depiction of the region in the (µ, ν) plane where the tumor cell population
is supercritical (the region below the line in (10)), displayed here on a logarithmic scale for two
cases (λ1  |λ0| and λ1 ∼ |λ0|). The two curves are drawn assuming r1 = 0.0162 (per hour) and
d1 = 0.015, and r0 = 0.04 and d0 = 0.08 for the λ1  |λ0| case (baseline parameter regime), and
r0 = 0.004 and d0 = 0.008 for the λ1 ∼ |λ0| case. Since the slope of (10) is λ1/|λ0| > 0, and it
intercepts the ν-axis at ν = λ1, the population is supercritical whenever ν ≤ λ1, independently
of the relationship between λ0 and λ1 (region A). When phenotypic memory is short (ν > λ1),
the population can still be supercritical, the degree to which depends on the slope λ1/|λ0| (region
B for λ1  |λ0| and regions B+C for λ1 ∼ |λ0|). (b) Time-evolution of the expected number
(log-scale) of type-0 cells (dark curve) and type-1 cells (light curve) during continuous anti-cancer
treatment, assuming no transiently resistant cell is present at detection (m = 0), calculated using
(3). Parameter values are r0 = 0.04 (per hour), d0 = 0.08, r1 = 0.0162, d1 = 0.015, µ = 4 · 10−5,
ν = 4 · 10−4, η = 0, ξ0 = ξ1 = 0, n = 106 and m = 0. (c) Same as (b), except now r0 = 0.004 (per
hour) and d0 = 0.008.
If we assume d1 = 0, i.e. type-1 cells have a stem-like ability to proliferate indefinitely, the first
condition implies that even single-generation phenotypic memory may be sufficient to confer long-
term resistance, while the second condition implies that even non-heritable traits, e.g. stochastic
variation in gene transcription, may be able to save the tumor from extinction.
To further elucidate the coevolutionary dynamics between type-0 and type-1 cells, we show in
Figure 2b the long-term expected behavior of the population in the baseline parameter regime,
assuming no transiently resistant cell is present at detection (m = 0). When the anti-cancer agent
is applied, sensitive type-0 cells initially die at a fast rate, while a small fraction of them adopts
the resistant type-1 phenotype. Eventually, the population settles into an equilibrium where back-
and-forth epimutations of type-0 cells and reversions of type-1 cells drive an expansion of both
subpopulations, albeit at a slow rate. Once the type-1 population has reached a sufficient size,
we can expect it to develop more permanent resistance mechanisms, as is discussed further in
subsequent sections. In Figure 2c, we show long-term expected behavior under an alternative
parameter regime, where |λ0| is reduced so that it is of the same order as λ1 (λ1 ∼ |λ0|). In this
regime, type-0 decay is less rapid under anti-cancer treatment, which implies both that the type-1
population builds up more quickly, and that more type-0 cells remain at equilibrium. Note that the
equilibrium proportion between type-1 and type-0 cells can in general be computed using expression
(5) above.
By examining cell behavior at the individual level, we observe that each type-0 cell is almost
guaranteed to go extinct in the baseline regime (it survives with probability 0.005%), while each
type-1 cell survives with 4.9% probability (Equation C.1). Despite these odds, the anti-cancer agent
is unsuccessful in eradicating the drug-sensitive population due to the dynamic switching between
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phenotypes. In fact, the population as a whole is guaranteed to survive treatment (Equation C.2),
which is due to the substantial buffer of type-1 cells that accumulates through type-0 epimutations
at the start of treatment and protects the somewhat fragile type-1 population against extinction.
These survival probabilities are generally robust to significant variation in r0, d0, r1 and d1, as we
display in Table H.1 in Appendix H. The main exception occurs when r1 and d1 are changed so
that the population becomes subcritical, in which case there is no chance of tumor survival. This
transition from guaranteed tumor survival to guaranteed extinction can be quite abrupt, as we
explore further in Section 4.2.
The above example allows us to glean two important insights: First of all, the relatively rapid
adoption of an epigenetically-mediated resistant phenotype places less restrictions on the robustness
of such a phenotype than what is the case for a rare genetic variant arising through mutation. Thus,
even a barely viable non-genetic phenotype may allow the tumor population to escape anti-cancer
therapy with 100% probability, in the absence of any more permanent resistance mechanisms.
Secondly, a tumor population that appears to be static or slow-growing at the population level
may in fact be driven be rapid switching dynamics at the single cell level, and uncovering the exact
dynamics may be crucial to understanding how the population responds to treatment, which is the
subject of our next section.
4.2 Tumor survival when switching dynamics are perturbed
Targeted epigenetic agents, e.g. inhibitors of DNA methylation and histone deacetylation, have been
considered both as a means of reversing the tumorigenic potential of cancer cells and of resensitizing
resistant cells to anti-cancer therapy (see e.g. [42, 43, 44, 45, 46]). In this section, we examine how
the probability of tumor survival under continuous anti-cancer treatment depends on the rate of
epimutation (µ) and reversion (ν). We then extract insights into the potential benefits of a joint
application of an anti-cancer agent, aimed at killing the tumor bulk, and an epigenetic drug, aimed
at disrupting the phenotypic switching dynamics.
The probability of survival of the tumor cell population, derived in Appendix C, is shown in
Figure 3a as a function of µ and ν. We consider first the case where no transiently resistant
cell preexists treatment (m = 0) and permanent resistance mechanisms are absent (η = 0 and
ξ0 = ξ1 = 0). We observe transitions in the dynamics around threshold values of µ
′ ∼ 10−6
and ν ′ ∼ 10−3 per hour. The latter threshold reflects a regime change from supercriticality to
subcriticality, since the baseline value for the net birth rate λ1 is of order 10
−3 per hour (the
population is supercritical below the ’critical curve’ in Fig 3a; see Section 4.1). When the population
is subcritical, the tumor goes extinct with 100% probability, since the high reversion rate ν to
sensitivity makes it impossible for type-1 cells to expand under treatment. In the supercritical
regime, there is always some positive probability that the tumor survives, although this probability
will be small for low epimutation rates (µ  10−6). For example, the tumor survival probability
corresponding to µ = 10−10 and ν = 10−4 in Figure 3a is 0.017%, since in this case, epimutations are
so infrequent that the type-1 state is unlikely to be adopted by any type-0 cell before the population
goes extinct. For high epimutation rates (µ 10−6), however, the type-1 buffer that accumulates at
the start of treatment becomes so large that tumor survival is guaranteed whenever the population
is supercritical, while extinction is guaranteed whenever the population is subcritical.
The threshold value µ′ ∼ 10−6 per hour represents the minimal epimutation rate at which tumor
survival is certain, given a supercritical population. In Appendix F, we show that the epimutation
rate at which the survival probability is at least 1− u (u 1) is
µ′ ≈ |λ0| log u
n log(d1/r1)
. (11)
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Figure 3: (a) Probability that the tumor survives continuous anti-cancer therapy, as a function
of µ and ν, assuming n = 106 and m = 0 and the absence of permanent resistance mechanisms
(η = 0 and ξ0 = ξ1 = 0), calculated using (C.2). The black dotted curve (’critical curve’) separates
the regions in the (µ, ν) plane where the population is subcritical (top) and supercritical (bottom).
This curve can be extracted from expression (10) upon logarithmic scaling (see Fig 2a). Region (I)
in the figure indicates a parameter regime where inhibiting epimutations (decreasing µ) with an
epigenetic drug can be an effective treatment strategy, whereas inducing reversions (increasing ν)
does little. The reverse is true in the parameter regime of region (II), where a slight perturbation
to the reversion rate ν can guarantee eradication of the tumor cell population. (b) Same as (a),
now assuming η = 4 ·10−7 (per hour) and ξ0 = ξ1 = 10−7 (per cell division), calculated using (G.5).
(c) Same as (a), now assuming n = 106 · 0.999 and m = 106 · 0.001, calculated using (C.2). Other
parameter values are r0 = 0.04 (per hour), d0 = 0.08, r1 = 0.0162, d1 = 0.015, µ = 4 · 10−5 and
ν = 4 · 10−4.
The threshold value µ′ thus depends on the drug-sensitivity λ0 of type-0 cells, the robustness of the
resistant phenotype (d1/r1 is the extinction probability of a type-1 clone, assuming no epimutations
or reversions, see e.g. [47]), and the initial population size n. An order of magnitude change in
λ0 or n will result in an order of magnitude change in µ
′, and in Table H.2 in Appendix H, we
show some examples of sensitivity to r1 and d1. For the baseline parameter regime and u = 0.001,
expression (11) yields µ′ ≈ 3.59 · 10−6 per hour, compared to a type-0 birth rate of r0 = 0.04 per
hour. This implies that if the resistant phenotype is adopted once in every 10,000 cell divisions
during treatment, the tumor is guaranteed to survive, even if no resistant cell preexists in the
population. For larger tumor sizes, e.g. n = 108 or n = 1010 cells, the required adoption rate lowers
to once every 106 and once every 108 cell divisions, respectively, which are frequencies typical of
resistance-conferring mutations (Appendix A). Since epigenetic modifications and other non-genetic
mechanisms can operate much faster, the above discussion implies that the mere possibility of non-
genetically conferred resistance can all but guarantee its emergence, especially when the tumor is
large at detection.
It is worth noting that the transition from guaranteed tumor survival to guaranteed extinction
in Figure 3a is much more gradual around the threshold value µ′ ∼ 10−6 per hour on the µ-axis
than around the critical value ν ′ ∼ 10−3 on the ν-axis. This reflects the asymmetric role of type-
0 and type-1 cells, and of epimutations and reversions, in the evolutionary dynamics. Lowering
the epimutation rate µ will reduce the type-1 buffer that accumulates at the start of treatment,
which gradually impairs the collective survival prospects of type-1 cells. On the other hand, since
any reversion from type-1 to type-0 effectively amounts to cell death in our setting, increasing
the reversion rate ν will directly affect the survival prospects of individual type-1 cells. As long
as ν is smaller than the critical value, each type-1 cell has some positive probability of persisting
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therapy, and given a sufficiently large type-1 buffer (i.e. sufficiently high epimutation rate µ), the
tumor as a whole can be guaranteed to survive. Once ν increases above the critical value, however,
each individual type-1 cell becomes certain to go extinct, and the same goes for the tumor as a
whole, no matter how large the buffer is. This explains why for high epimutation rates (µ 10−6),
we observe such a sharp transition between guaranteed tumor survival and guaranteed extinction
across the critical curve for ν.
Identifying where a particular cancer cell population falls within the (µ, ν) parameter space can
yield important insights into the relative attractiveness of targeting µ and ν with an epigenetic drug,
and the degree to which these parameters should be perturbed. When µ ∼ 10−6 and ν  10−3
per hour, for example (region (I) in Fig 3a), inhibiting epimutations (reducing µ) may significantly
reduce the tumor survival probability, while inducing reversions (increasing ν) may accomplish little.
When µ  10−6 and ν ∼ 10−3 per hour, however (region (II) in Fig 3a), a slight perturbation to
the reversion rate may be the difference between certain tumor survival and certain extinction.
This suggests that even if no resistant cell preexists treatment, it may be more effective to revert
resistant cells created during the initial stages of therapy than to prevent their emergence. We also
note the importance of identifying the relationship between ν and λ1 for therapeutic considerations.
Indeed, recognizing that a small perturbation to the average retention of the resistant phenotype
may yield significant treatment benefits can help minimize the risk of any unwanted side effects of
the epigenetic treatment.
For the case where permanent resistance mechanisms are assumed (η > 0 and ξ0, ξ1 > 0), the
probability of tumor survival can be derived by solving a system of nonlinear equations as shown
in Appendix G. Figure 3b shows that in this case, the tumor can survive even if the population
of type-0 and type-1 cells is subcritical. Indeed, if the epimutation rate µ is sufficiently high, the
large type-1 buffer created at the start of treatment may allow even a subcritical type-1 phenotype
to hold off extinction long enough for bona fide resistance to develop.
If we assume that a significant number of resistant cells preexists therapy (m 0), the survival
probability becomes insensitive to changes in µ under treatment, since the type-1 buffer needed
to save the tumor from extinction will already be present at the onset (Fig 3c). It remains true,
however, that a small perturbation to the reversion rate can turn certain therapy failure into certain
success.
4.3 Pathway to stable resistance and rate of acquisition
We now examine the mode and speed of stable resistance acquisition (η > 0 and ξ0, ξ1 > 0) during
continuous anti-cancer treatment. In Figure 4a, we show the average time at which the first stably
resistant (type-2) cell arises in the population, as a function of the epimutation rate µ, given that
a type-2 cell emerges before extinction of the population. In Figure 4b, we show the probability of
the conditioning event, and the probability that stable resistance is conferred through mutation as
opposed to epigenetic reprogramming.
We first assume that no transiently resistant (type-1) cell is present at the onset (m = 0; solid
curves). We again note a transition in the dynamics around a threshold value of µ ∼ 10−6 per
hour, and interestingly, the average time to resistance is both non-monotonic and highly variable
in µ (Fig 4a; solid curve). When µ is small (µ  10−6), epimutations are so infrequent that the
tumor can only survive via mutation in the type-0 population. Since type-0 cells decay at a fast
rate, any such mutation has to occur early if it is to occur at all. As µ increases, the burden of
saving the tumor from extinction moves increasingly from type-0 to type-1 cells (Fig 4b; light solid
curve), which creates a new pathway for resistance acquisition at a later time. Once the role of
type-0 and type-1 cells in conferring resistance becomes stabilized, however, the mean acquisition
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Figure 4: (a) Expected time at which the first type-2 cell emerges in the population as a function
of the epimutation rate µ, conditioned on the event that a type-2 cell emerges before extinction,
first assuming n = 106 and m = 0 (solid curve), and then n = 106 · 0.999 and m = 106 · 0.001
(dashed curve). Produced via simulation by running the process until a type-2 cell emerged on 1000
different occasions and calculating an average. (b) Probability of type-2 emergence (dark curves)
and probability that the first type-2 cell arises through mutation (light curves). Other parameter
values are r0 = 0.04 (per hour), d0 = 0.08, r1 = 0.0162, d1 = 0.015, ν = 4 · 10−4, η = 4 · 10−8 and
ξ0 = ξ1 = 10
−7 (per cell division).
time starts to decrease as µ increases, since the type-1 population is created earlier and in greater
numbers. If a significant number of type-1 cells is present at the onset (m 0), resistance will be
guaranteed to form independently of the epimutation rate under treatment (Fig 4b; dark dashed
curve), and the expected acquisition rate will be insensitive to µ for small µ (Fig 4a; dashed curve),
since resistance will most likely develop through the type-1 population that preexists treatment
(Fig 4b; light dashed curve).
In Figure 5a, we consider time to resistance as a function of the reversion rate ν instead.
We again observe non-monotonicity and significant variability, with resistance development being
slowest around the critical value ν ∼ 10−3 per hour. In this case, however, the rate of resistance
acquisition is generally insensitive to changes in ν for small ν, and the transition around the critical
value ν ′ ∼ 10−3 is much sharper than around the threshold value µ′ ∼ 10−6 in Figures 4a and
4b. For small ν, stable resistance is mediated primarily through epigenetic reprogramming (Fig 5b;
light solid curve), so time to resistance is governed by the size of the type-1 population. Since the
net proliferation rate λ1−ν determines net growth of type-1 cells, the rate of resistance acquisition
is not affected by ν as long as ν  λ1. As ν approaches λ1, however, the net proliferation rate λ1−ν
approaches zero, and epigenetic reprogramming slows down considerably. As ν increases above λ1,
the population becomes subcritical, and the probability of tumor survival decreases abruptly (Fig
5b; dark solid curve), similarly to what we observed in Section 4.2. During this sharp transition,
the burden of saving the tumor from extinction moves from the type-1 to the type-0 population
(Fig 5b; light solid curve), and since any mutation in the type-0 population must occur early if it
is to occur at all, the time to resistance also decreases abruptly as ν enters the subcritical regime.
Contrary to Figures 4a and 4b, we now observe the same qualitative behavior for the m = 0 (solid
curves) and m 0 (dashed curves) cases, which mirrors our discussion from Section 4.2.
The above observations add an interesting layer to our earlier discussion on the effect of ma-
nipulating µ and ν on treatment outcome. As an example, when µ  10−6 per hour, inhibiting
epimutations (reducing µ) may not do much to prevent acquired resistance, but it can slow it down
considerably. Moreover, any perturbation to the reversion rate ν when it is around its critical value
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Figure 5: (a) Expected time at which the first type-2 cell emerges in the population as a function
of the reversion rate ν, conditioned on the event that a type-2 cell emerges before extinction,
first assuming n = 106 and m = 0 (solid curve), and then n = 106 · 0.999 and m = 106 · 0.001
(dashed curve). Produced via simulation by running the process until a type-2 cell emerged on 1000
different occasions and calculating an average. (b) Probability of type-2 emergence (dark curves)
and probability that the first type-2 cell arises through mutation (light curves). Other parameter
values are r0 = 0.04 (per hour), d0 = 0.08, r1 = 0.0162, d1 = 0.015, µ = 4 · 10−5, η = 4 · 10−8 and
ξ0 = ξ1 = 10
−7 (per cell division).
may dramatically affect the rate of resistance acquisition. Note that when µ is around its threshold
value of µ ∼ 10−6, resistance will be expected to arise extremely late, while still being guaranteed
to develop. The former is a consequence of the slow-cycling nature of the resistant phenotype, while
the latter is a consequence of its rapid adoption under treatment. This is an important feature
of epigenetically-mediated resistance, and this behavior stands in stark contrast to more robust
genetically-resistant phenotypes that are adopted less frequently.
4.4 Evaluation of combination treatment strategies
To further illustrate how our model can aid medical decision-making, we now examine a combination
treatment of an anti-cancer agent and a hypothetical epigenetic drug that directly targets the rates
of epimutation (µ) and reversion (ν). Our main questions are whether such a combination is likely
to be effective, and whether the epigenetic drug should be applied as pretreatment, posttreatment,
or simultaneously with the anti-cancer agent. To evaluate treatment outcome, we use the following
expression for the probability that a successful type-2 cell (i.e. a type-2 cell that gives rise to a
clone that does not go extinct) has emerged by time t,
1− exp
(
−λ2
r2
∫ t
0
(ξ0r0φ0(s) + ξ1r1φ1(s) + ηφ1(s))ds
)
(12)
derived in Appendix G. Using (3), we can derive explicit expressions for the integrals in (12) as
follows: ∫ t
0
φ0(s)ds = −β
σ
(1− eσt)− α
ρ
(1− eρt),∫ t
0
φ1(s)ds = −γβ
σ
(1− eσt) + δα
ρ
(1− eρt),
(13)
assuming σ 6= 0 and ρ 6= 0. These two integrals can be interpreted as the average ’total mass’ of
type-0 and type-1 cells, respectively, up until time t.
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Figure 6: (a) Schematic representation of one treatment cycle in the schedules considered. Each
schedule is identified by a distinct color which is also applied in (b) and (c). (b) Time-evolution
of the probability of successful type-2 emergence, first when the anti-cancer agent is applied alone
during the first two blocks of each cycle (blue curve), and then for the four schedules depicted in
(a), calculated using (12). Under the anti-cancer agent, r0 = 0.04 (per hour) and d0 = 0.08, while
off it, r0 = 0.04 and d0 = 0.0015. Under the epigenetic drug, µ = 4 · 10−7 and ν = 4 · 10−2, while
off it, µ = 4 · 10−5 and ν = 4 · 10−4. The dashed red line shows a modification of Schedule A where
r0 = d0 = 0.04 during the first 2-day block of the first treatment cycle. (c) Time-evolution of the
expected number of type-1 cells for the same schedules as considered in (b), calculated using (3).
Parameters not mentioned above are fixed at r1 = 0.0162 (per hour), d1 = 0.015, η = 4 · 10−7,
ξ0 = ξ1 = 10
−7 (per cell division), n = 106 · 0.999 and m = 106 · 0.001. The vertical broken lines in
(b) and (c) signify treatment cycles.
We assume that each treatment cycle consists of three two-day blocks and we examine four
schedules. In Schedule A, the epigenetic drug is applied as pretreatment to the anti-cancer agent,
whereas in Schedules B, C and D, the anti-cancer agent is applied during the first two blocks of
each cycle, and the epigenetic drug is applied during the first, second or third block, respectively
(Fig 6a). We show results assuming that the epigenetic drug increases the reversion rate ν by two
orders of magnitude and decreases the epimutation rate µ to the same extent, while noting that
our insights are robust to significant variation in this assumption (Appendix H). We also note that
the relatively short duration of each treatment cycle is a function of the rapid in vitro dynamics of
our baseline parameter regime. If each rate constant in the baseline regime is reduced by an order
of magnitude, which may more accurately represent in vivo dynamics, the results shown below will
continue to hold unchanged if we use 60-day treatment cycles instead of 6-day cycles.
Figure 6b indicates that whereas the anti-cancer agent alone is guaranteed to fail, combining
it with a drug that disturbs the epigenetic switching dynamics has the potential to eradicate the
tumor with high probability. Pretreatment with the epigenetic drug performs the worst by far
(Schedule A; red solid curve), which is due to the fast proliferation of type-0 cells in the absence of
the anti-cancer agent, and the relatively fast acquisition of the resistant phenotype in its presence.
This both increases the risk of a resistance-conferring mutation during the initial pretreatment
phase, and ensures that type-1 cells killed during this phase are rapidly replenished once the anti-
cancer agent is applied (Fig 6c). Schedule A continues to perform the worst even if we assume
that the tumor population cannot expand beyond its initial size due to spatial constraints, which
we model by setting r0 = d0 = 0.04 per hour during the initial pretreatment phase (red dashed
curves). This implies that pretreatment with an epigenetic drug may not be judicious when drug-
sensitive type-0 cells proliferate too rapidly in the absence of the anti-cancer agent and/or when
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the resistant type-1 phenotype is adopted too quickly under treatment. This insight is consistent
with experimental findings by Sharma et al. [13], where the authors observe that simultaneous
application of erlotinib and the histone deacetylase inhibitor TSA to PC9 cells eliminates the
emergence of resistant clones, whereas a substantial number of such clones arises when extended
pretreatment with TSA is followed by exposure to erlotinib.
Focusing now on the other three schedules (B, C and D), we note that the number of type-1
cells remaining at the end of each treatment cycle is similar for each of them (Fig 6c). Schedule
B performs the best, however, since it contains the type-1 population as early as possible in each
cycle, which reduces the ’total mass’ of type-1 cells in the presence of the anti-cancer agent and
slows down epigenetic reprogramming by (12). This finding is robust to significant perturbation of
main model parameters, and the relative attractiveness of Schedule B over the other schedules can
be much more pronounced than shown here, e.g. when the rate of epimutation (µ) or epigenetic
reprogramming (η) is higher, or the initial tumor size (n+m) is larger (Appendix H). As an example,
when n = 108 · 0.999 and m = 108 · 0.001, with other parameters unchanged, resistance will be
all but guaranteed to form in Schedules A, C and D, while Schedule B is capable of preventing
resistance via epigenetic reprogrammming with high probability (Fig H.1d).
Our results indicate both that combining an epigenetic drug with an anti-cancer agent can vastly
outperform anti-cancer only treatment, and that the epigenetic drug should be applied simultane-
ously with the anti-cancer agent. These insights are consistent with experimental findings e.g. by
Su et al. [32], who find that in vitro inhibition of the NfκB p65 and MEK/ERK signaling axes
in melanoma, in combination with the anti-cancer agent vemurafenib, significantly outperforms
monotherapy, by arresting cell-state transitions to a drug-tolerant state. In Goldman et al. [33],
the authors find that applying the SFK inhibitor dasatinib in vivo on days 8-11 of breast cancer
treatment, following two maximum tolerated doses of the anti-cancer agent docetaxel (DTX) on
days 2 and 5, is much more effective than DTX-alone treatment. They further show that this treat-
ment is preferable to applying dasatinib on days 2-5 (Schedule I), which shows modest improvement
over stand-alone DTX treatment, and applying dasatinib on days 14-17 (Schedule II), which shows
no improvement over stand-alone treatment. Although the authors in [33] refer to Schedule I as a
’simultaneous schedule’, the application of dasatinib on days 2-5 should not necessarily be expected
to inhibit epimutations following the large DTX dose on day 5. Application on days 8-11 may be
better timed both to revert already drug-tolerant cells to sensitivity and to ’target the induction
phase of DTX-induced cell state transition’ as the authors put it. Nevertheless, this example serves
as an important reminder that actual in vivo dynamics are likely to be more complex than captured
by our simple abstraction. As an example, if the epimutation rate µ is influenced by anti-cancer
treatment, but this effect is delayed, there may be reason to delay application of the epigenetic
drug. Any substantial presence of drug-tolerant cells that preexist treatment will then create a
trade-off between attacking these two temporally distinct sources of resistance. Indeed, a more
complete mechanistic and quantitative understanding of the dynamics of phenotypic switching at
the single-cell-level, and how these dynamics are influenced by anti-cancer treatment, will give rise
to more complex mathematical questions, as we address further in the discussion section.
5 Discussion
The pervasiveness of acquired drug resistance remains one of the major challenges during clinical
management of cancer patients. We have established through our evolutionary modeling that non-
heritable stochastic fluctuations in gene expression and short-term epigenetic modifications can
’save’ a tumor from extinction in the absence of any more permanent resistance mechanisms. We
have also seen that the potential for rapid adoption of non-genetic resistance implies that such
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resistance can be all but guaranteed to develop, even if no resistant cell preexists treatment and the
resistant phenotype is barely viable. This suggests ample opportunity for non-genetic mechanisms
to induce failure of conventional anti-cancer therapy, and it may help explain why so many tumors
develop resistance without acquiring mutations in drug targets or activated pathways [7].
Throughout, we have highlighted how thinking in terms of our mathematical model can aid
medical decision-making. In Section 4.2, we saw how a quantitative understanding of the dynamics
of epimutation and reversion at the single-cell level can yield important insights into which param-
eter to attack with an epigenetic drug and the extent to which it needs to be perturbed. As an
example, when the average retention 1/ν of the resistant phenotype is near a critical value of 1/λ1,
a slight perturbation to ν can turn guaranteed treatment failure into guaranteed success. In Section
4.3, we further saw how a quantitative understanding of the underlying switching dynamics, and
the rate at which any permanent resistance mechanisms are adopted, can allow us to predict the
mode and time scale of resistance acquisition. We noted that when the resistant type-1 phenotype
is slow-cycling, the expected time at which permanent resistance arises in the population can vary
greatly depending on the epimutation rate µ, and that when µ is near a certain threshold value,
resistance can be expected to develop extremely late while still being guaranteed to emerge.
In Section 4.4, we finally observed that combining an epigenetic drug with an anti-cancer agent
can significantly outperform anti-cancer only treatment, and that the epigenetic drug should be
applied simultaneously with the anti-cancer agent rather than as pretreatment or posttreatment.
We also noted that pretreatment with the epigenetic drug is not advisable especially when drug-
sensitive cells proliferate too rapidly in the absence of the anti-cancer agent, or the resistant pheno-
type is adopted too quickly in its presence. It should of course be stressed that our model is highly
simplified. As an example, we have not assumed any delay in the potential drug-induced adop-
tion of transient resistance under anti-cancer treatment, and we have not assumed any interaction
between the anti-cancer agent and the epigenetic drug. Also, whereas we have assumed that the
drug-resistant phenotype is continuously slow-cycling, it may respond to drug pressure by entering
a quiescent state before resuming proliferation. Finally, our model does not incorporate spatial
effects or toxicity constraints, all of which may call for modifications or extensions to the model as
our biological understanding accumulates.
Our analysis represents, as far as we know, a first attempt toward a deeper understanding of
the evolutionary dynamics of a population that is able to employ transiently resistant cell states to
escape anti-cancer therapy. The model presented is flexible in that it enables description of a variety
of sources of phenotypic heterogeneity, and the analytical expressions we have derived allow for easy
estimation and comparison of treatment outcomes under different regimens. Our investigation is
theoretical in nature, however, and the true power of our mathematical model will only be realized
through a more complete mechanistic understanding of the dynamics of phenotypic switching at
the single-cell-level, and through new methods to infer these dynamics quantitatively. Our hope is
that a combined biological and mathematical effort will pave the way toward the design of novel
therapeutic strategies, as well as mathematical optimization of already available drug combinations
and treatment schedules [48, 49].
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Appendix A Parametrization
To parametrize the model, we rely on Sharma et al.’s [13] investigation of an EGFR-mutant non-
small-cell lung cancer (NSCLC) population (PC9) treated with 2 µM erlotinib, with fresh drug
added every 3 days, and Hata et al.’s [37] study of the evolution of resistance conferred by the
EGFRT790M gatekeeper mutation in PC9 cells.
Most of the discussion in the main text concerns behavior in the presence of an anti-cancer
agent, so we start with those dynamics. Following Hata et al. [37], we assume that drug-tolerant
type-1 cells give birth at rate r1 = 0.0162 per hour and die at rate d1 = 0.015 per hour, and that
stably resistant type-2 cells give birth at rate r2 = 0.04 and die at rate d2 = 0.0015. Although
these rates apply to treatment with 300 nM gefitinib as opposed to 2 µM erlotinib, viability curves
presented in [13] indicate that it is reasonable to assume similar rates for the case of 2 µM erlotinib
treatment.
In Sharma et al. [13], the authors report that under 9 days of continuous anti-cancer treatment,
almost all cells in the population die, while persister cells corresponding to around 0.27%± 0.21%
of the original population survive. Assuming exponential decay of the drug-sensitive type-0 popu-
lation, we estimate a net birth rate of λ0 = −0.04 per hour for type-0 cells and set r0 = 0.04 and
d0 = 0.08, where we assume without loss of generality that the anti-cancer agent increases the death
rate of type-0 cells without affecting their birth rate (the birth rate of type-0 cells in the absence
of the anti-cancer agent is r0 = 0.04 as is discussed below). Note that if we assume instead that
the drug decreases the birth rate of type-0 cells, with the net birth rate λ0 = −0.04 unchanged, the
type-0 population will decay at the same net rate as before, but the mutation rate r0ξ0 of type-0
cells will decrease proportionally to the decrease in r0. We can therefore view variation in the effect
of the drug on the birth rate r0 as equivalent to variation in the mutation rate ξ0.
The rates µ of epimutation and ν of reversion are more difficult to estimate, since it is not clear
in [13] how many of the type-1 persister cells that survive the first 9 days of treatment are present
at the onset. However, the authors do conclude from experiments applying the histone deacetylase
inhibitor TSA as pretreatment to erlotinib that type-1 cells do emerge de novo during treatment.
For our baseline parameter regime, we will assume that around half the cells that survive the first 9
days of treatment are present at the onset and set µ = 4 · 10−5 per hour accordingly, which implies
that an epimutation occurs once in every 1,000 divisions of a type-0 cell. In determining ν, we
assume that cells transition more freely out of the resistant state than into it and set ν = 4 · 10−4,
which is consistent with observed phenotypic switching dynamics between persister cells and normal
cells in Escherichia coli bacterial populations [50], and between stem-like and non-stem-like cells
in breast cancer [31].
The point mutation rate per nucleotide per cell division has been estimated as 5 · 10−10 [47].
To obtain the rate of mutations that confer resistance to anti-cancer therapy, this number needs to
be multiplied by the number of resistance-conferring point mutations. Following e.g. [37] and [51],
we assume a baseline rate of ξ0 = ξ1 = 10
−7 per cell division, although a reasonable range can be
anywhere from 10−9 to 10−5, which is the range suggested by [47] for mutations leading to cancer.
This assumption on ξ0 and ξ1 translates into a mutation rate of r0ξ0 = 4 · 10−9 per hour for type-0
cells and r1ξ1 = 1.62 · 10−9 per hour for type-1 cells.
As for the rate η of epigenetic reprogramming, we note that measurements provided by Bintu
et al. [41] of the dynamics of epigenetic silencing under recruitment of chromatin regulators suggest
that it may be natural to assume that η is around 1-2 orders of magnitude lower than µ. We will
apply η = 4 · 10−7 or η = 4 · 10−8 as our baseline rate depending on the context, which is 2-3
orders of magnitude smaller than µ, and 1-2 orders of magnitude larger than the mutation rates
r0ξ0 and r1ξ1. As is the case for the mutation rate, one can expect significant variation in the
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Presence of drug
r0 0.04
d0 0.08
r1 0.0162
d1 0.015
µ 4 · 10−5
ν 4 · 10−4
η 4 · 10−7 or 4 · 10−8
ξ0 = ξ1 10
−7
r2 0.04
d2 0.0015
Table A.1: Baseline parameter regime in the presence of an anti-cancer agent. All rates are mea-
sured per hour, except the mutation rates ξ0 and ξ1, which are measured per cell division.
epigenetic reprogramming rate depending on the cancer type, the anti-cancer agent being applied
and the concentration of this agent. We also note that ‘stable epigenetic resistance’ may not even
be a well-defined concept if epigenetic reprogramming occurs in a multi-stage or continuous fashion,
with each stage leading to an increasingly stable phenotype, which is either less likely to revert
back to sensitivity once removed from drug or does so on a longer time scale.
In the main text, we show all results assuming an initial population size of 106 cells, following the
in vitro experiments conducted by Sharma et al. We note that 106 refers to the effective population
size, i.e. those tumor cells that are capable of undergoing phenotypic switching, which may only
apply to a subset of tumor cells [52]. We also note that the initial population size should be viewed
in context of the mutation rates r0ξ0 = 4 · 10−9 and r1ξ1 = 1.62 · 10−9 and the reprogramming
rates η = 4 · 10−7 or η = 4 · 10−8, since the relationship between these three parameters largely
determines the dynamics of resistance acquisition.
The only section in the main text where tumor dynamics in the absence of an anti-cancer agent
are considered is Section 4.4. Since most of the data referenced above concerns behavior in the
presence of drug, we will mostly assume that the dynamics on and off drug are identical, with the
important exception of the birth and death rate of type-0 cells, which we assume to be r0 = 0.04
and d0 = 0.0015 off drug, following Hata et al. [37]. The resulting parameter values (Table A.2)
therefore reflect the qualitative setting where type-0 cells proliferate rapidly in the absence of drug
but die rapidly in its presence, and type-1 cells proliferate slowly both on and off drug. The
assumption that type-1 cells are at a selective disadvantage off drug is not essential to our results,
as is discussed in Appendix H below.
We finally note that according to the above dynamics, type-1 cells will constitute around 0.11%
of the population during long-term expansion in the absence of drug and at the start of treatment.
In the main text, we generally consider both the case where no type-1 cell is present at the start of
anti-cancer treatment (m = 0), and the case where type-1 cells constitute 0.1% of the population
at the onset (m 0).
Appendix B Two-type Markovian branching processes
Here, we derive expression (3) in the main text and describe some of its properties. For the case
η = 0 and ξ0 = ξ1 = 0, our model reduces to a two-type continuous-time Markovian branching
process [39]. Let X(t) = (X0(t), X1(t)) denote such a process, where the two types are designated
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Absence of drug
r0 0.04
d0 0.0015
r1 0.0162
d1 0.015
µ 4 · 10−5
ν 4 · 10−4
η 0
ξ0 = ξ1 10
−7
r2 0.04
d2 0.0015
Table A.2: Baseline parameter regime in the absence of an anti-cancer agent. All rates are measured
per hour, except the mutation rates ξ0 and ξ1, which are measured per cell division.
as type-0 and type-1. Associated with X(t) is the mean matrix M(t) = {mij(t) : (i, j) ∈ {0, 1}2},
defined by
mij(t) = E[Xj(t)|X(0) = ei], (i, j) ∈ {0, 1}2,
where ei denotes the unit vector with 1 in the i-th coordinate, and the infinitesimal generator
A = {aij : (i, j) ∈ {0, 1}2}, which satisfies
M(t) = exp(At), t ≥ 0.
We can interpret mij(t) as the mean number of type-j particles alive at time t, given that the
process is started by a single type-i cell, and aij as the infinitesimal rate at which a type-i cell
produces a type-j cell. We assume that a12, a21 > 0, i.e. the rates of switching between types are
strictly positive. For further discussion on the above matrices, see [39].
Let φ
(n,m)
0 (t) and φ
(n,m)
1 (t) denote the mean number of type-0’s and type-1’s alive at time t,
assuming initial conditions (X0(0), X1(0)) = (n,m), where n and m are nonnegative integers with
n+m > 0. Using the mean matrix, we can easily compute these means as
[φ
(n,m)
0 (t) φ
(n,m)
1 (t)] = [n m] M(t). (B.1)
Note that the infinitesimal generator A possesses distinct real eigenvalues ρ < σ given by
a11 + a22 ±
√
(a11 − a22)2 + 4a12a21
2
, (B.2)
which follows from our assumption that a12 > 0 and a21 > 0. The eigenvalues of M(t) = exp(At)
are then easily obtained as eρt and eσt. If we define δ := (a11 − ρ)/a21 and γ := (σ − a11)/a21, it
is easily established that v = [1 δ] and w = [1 γ] are left eigenvectors of A with respect to ρ and
σ, respectively. Decomposing [n m] in terms of v and w, we can then compute the means in (B.1)
explicitly as
φ
(n,m)
0 (t) =
nδ +m
δ + γ
eσt +
nγ −m
δ + γ
eρt,
φ
(n,m)
1 (t) =
γ(nδ +m)
δ + γ
eσt − δ(nγ −m)
δ + γ
eρt.
(B.3)
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If we define α := (nγ −m)/(δ + γ) and β := (nδ + m)/(δ + γ), we can simplify these expressions
further to
φ
(n,m)
0 (t) = βe
σt + αeρt,
φ
(n,m)
1 (t) = γβe
σt − δαeρt.
(B.4)
Note that although we do not show it explicitly, the constants α and β depend on the initial
conditions (n,m), whereas γ, δ, σ and ρ are completely determined by the infinitesimal generator
A.
We next establish that that a11 − ρ > 0 and σ − a11 > 0, which will imply that γ > 0, δ > 0
and β > 0 in (B.3) and (B.4). By rewriting (B.3) as
φ
(n,m)
0 (t) =
n
δ + γ
(δeσt + γeρt) +
m
δ + γ
(eσt − eρt),
φ
(n,m)
1 (t) =
nδγ
δ + γ
(eσt − eρt) + m
δ + γ
(γeσt + δeρt),
and noting that ρ < σ, it will also follow that the expected number of type-0’s and type-1’s is
strictly positive for all t > 0, i.e. X(t) is a positive-regular process [39].
To show that a11 − ρ > 0 and σ − a11 > 0, we first note that since ρ is an eigenvalue for A,
we have (a11 − ρ)(a22 − ρ) = a12a21. By our assumption that a12, a21 > 0, the terms a11 − ρ and
a22 − ρ must then be nonzero and have the same sign. Using (B.2), we get since a12, a21 > 0:
ρ =
a11 + a22 −
√
(a11 − a22)2 + 4a12a21
2
<
a11 + a22 − |a11 − a22|
2
=
{
a11 if a11 ≤ a22
a22 if a11 > a22.
This implies that a11 − ρ > 0 or a22 − ρ > 0 depending on the relationship between a11 and a22.
Since a11 − ρ and a22 − ρ have the same sign, one being positive implies that the other one is as
well, so in both cases, we have a11 − ρ > 0 and a22 − ρ > 0. A similar argument confirms that
σ − a11 > 0.
Now let
φ(n,m)(t) := φ
(n,m)
0 (t) + φ
(n,m)
1 (t)
denote the expected total number of cells (type-0 and type-1) alive at time t, starting from n type-0
cells and m type-1 cells. By (B.4), we can write
φ(n,m)(t) = β(1 + γ)eσt + α(1− δ)eρt. (B.5)
We then obtain the following expressions for the expected size of a clone, at time t, started by a
single cell of each type:
φ(1,0)(t) =
δ(1 + γ)
δ + γ
eσt +
γ(1− δ)
δ + γ
eρt,
φ(0,1)(t) =
1 + γ
δ + γ
eσt − 1− δ
δ + γ
eρt.
(B.6)
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We conclude by discussing large-t asymptotics. Since σ > ρ, the long-run behavior will be domi-
nated by the former term in (B.3), (B.4), (B.5) and (B.6). In particular, we can write
φ
(n,m)
0 (t) = βe
σt + o(eσt),
φ
(n,m)
1 (t) = γβe
σt + o(eσt),
(B.7)
and
φ(1,0)(t) =
δ(1 + γ)
δ + γ
eσt + o(eσt),
φ(0,1)(t) =
1 + γ
δ + γ
eσt + o(eσt),
(B.8)
where o(eσt) denotes a function that satisifies o(eσt)/eσt → 0 as t→∞. Note that from (B.7), it is
clear that γ is the long-run ratio between type-1’s and type-0’s in the population, and from (B.8),
we see that δ is the long-run ratio between mean clone size started by a single type-0 cell vs. a
single type-1 cell. This gives an intuitive interpretation of δ and γ in (B.3), (B.4), (B.5) and (B.6),
while α and β depend on n, m, δ and γ through α = (nγ −m)/(δ + γ) and β = (nδ +m)/(δ + γ).
Appendix C Extinction probabilities
We continue to assume the absence of permanent resistance mechanisms (η = 0 and ξ0 = ξ1 = 0),
which implies that our model still reduces to a two-type branching process (X0(t), X1(t)). Define
p0 := P (X0(t) +X1(t) = 0 for some t|X0(0) = 1, X1(0) = 0),
p1 := P (X0(t) +X1(t) = 0 for some t|X0(0) = 0, X1(0) = 1),
as the extinction probabilities of clones started by a single cell of each type. Note that if we start
the process with a single type-0 cell, the initial event in the process will be a (i) cell division with
probability r0/(r0 +d0 +µ), (ii) cell death with probability d0/(r0 +d0 +µ), and a switch to type-1
with probability µ/(r0 + d0 + µ). If the initial event is a cell division, an additional type-0 cell
will be created and the process goes extinct if and only if both cells go extinct, which occurs with
probability p20. If the initial event is a switch between types, the new type-1 cell will go extinct
with probability p1. Therefore, by conditioning on whether the initial event is a division, death or
switch between types, we can derive the following conditions for p0 and p1:
p0 =
r0
r0 + d0 + µ
· p20 +
d0
r0 + d0 + µ
· 1 + µ
r0 + d0 + µ
· p1,
which yields
(r0 + d0 + µ) · p0 = r0p20 + d0 + µp1.
By the same argument for a process started with a single type-1 cell, we obtain the following
nonlinear system for p0 and p1:
(r0 + d0 + µ) · p0 = r0p20 + d0 + µp1,
(r1 + d1 + ν) · p1 = r1p21 + d1 + νp0.
(C.1)
When σ > 0 and the process is supercritical, we have p0 < 1 and p1 < 1 which are uniquely
determined by these two equations, while when σ < 0, we have p0 = 1 and p1 = 1 [39].
24
Note that the classification into supercritical and subcritical is independent of the initial condi-
tions (X0(0), X1(0)) = (n,m) (a change in initial conditions does not affect the extinction probabil-
ity of a single-cell derived clone). The initial conditions do however affect the survival probability
of the population as a whole. Indeed, the survival probability for a population starting with n
type-0 cells and m type-1 cells is
1− pn0pm1 , (C.2)
since the population goes extinct if and only if each individual type-0 cell and each individual type-1
cell goes extinct, which occurs with probability pn0p
m
1 by independence.
Appendix D Conditions for supercriticality
Here, we derive condition (7) in the main text. We again let (X0(t), X1(t)) denote the stochastic
process corresponding to the model in the absence of permanent resistance mechanisms (η = 0 and
ξ0 = ξ1 = 0).
Lemma 1. Assume λ0 < 0, λ1 > 0, µ > 0 and ν > 0.
(1) (X0(t), X1(t)) is subcritical if νλ0 + µλ1 < λ0λ1, critical if νλ0 + µλ1 = λ0λ1 and supercritical
if νλ0 + µλ1 > λ0λ1.
(2) A sufficient condition for supercriticality is λ1 ≥ ν.
Proof. It is trivial to check, by determining the sign of the larger eigenvalue σ in (4) in the main
text, that
(i) (X0(t), X1(t)) is subcritical if λ0 + λ1 < µ+ ν and νλ0 + µλ1 < λ0λ1.
(ii) (X0(t), X1(t)) is critical if λ0 + λ1 < µ+ ν and νλ0 + µλ1 = λ0λ1.
(iii) (X0(t), X1(t)) is supercritical if λ0 + λ1 ≥ µ+ ν or νλ0 + µλ1 > λ0λ1.
What remains to show is that the first condition is redundant in each case, and that (iii) is satisfied
when λ1 ≥ ν.
Note first that if λ1 ≥ ν, we have
νλ0 + µλ1 − λ0λ1 = λ0(ν − λ1) + µλ1 ≥ µλ1 > 0.
since λ0 < 0, µ > 0 and λ1 > 0, from which supercriticality follows. This establishes (2). Then
note that since λ1 ≥ ν implies νλ0 + µλ1 > λ0λ1, and we have ν − λ0 > 0, we get
νλ0 + µλ1 ≤ λ0λ1 ⇒ λ1 < ν ⇒ λ1 < µ+ ν − λ0,
which shows that the first condition in (i) and (ii) above is implied by the second condition. Using
what we have proven, we additionally have
λ0 + λ1 ≥ µ+ ν ⇒ λ1 ≥ ν ⇒ νλ0 + µλ1 − λ0λ1 > 0,
showing that the second condition in (iii) above contains the first one.
25
Appendix E Alternate version of the model
In our baseline model, we assume that epimutations and reversions can occur at any time during the
cell cycle. If we instead want a model where these events only occur at cell divisions, we proceed as
follows, assuming again the absence of permanent resistance mechanisms (η = 0 and ξ0 = ξ1 = 0).
Let u denote the probability of epimutation at each division of a type-0 cell and v denote the
probability of reversion at each division of a type-1 cell. A type-0 cell then divides into two type-0
cells at rate r0(1−u) and it produces one type-0 and one type-1 cell at rate r0u. Similarly, a type-1
cell divides into two type-1 cells at rate r1(1− v) and it produces one type-0 and one type-1 cell at
rate r1v. These dynamics can be captured by the infinitesimal generator
A =
[
r0(1− u)− d0 r0u
r1v r1(1− v)− d1
]
=
[
λ0 − r0u r0u
r1v λ1 − r1v
]
.
Note that this infinitesimal generator has the same form as the generator (1) for our baseline model
if we define µ := r0u and ν := r1v. This implies that the mean behavior of this new model is
identical to the mean behavior of our original model, and all expressions of Appendix B apply by
making the above substitution. The models are distinct, however, on a sample-path basis, which
is reflected e.g. in distinct extinction probabiltities. These probabilities are now determined by the
equations
(r0 + d0) · p0 = r0(1− u)p20 + d0 + r0up0p1,
(r1 + d1) · p1 = r1(1− v)p21 + d1 + r1vp0p1,
which in general yield different solutions to (C.1).
Appendix F Threshold value for µ
In the main text, we examine the survival probability of a tumor under continuous anti-cancer
therapy, assuming no transiently resistant cell is present at the start of treatment (m = 0). We
observe a threshold value µ′ which is the minimal epimutation rate that guarantees long-term
survival of the resistant population. Here, we are interested in deriving an expression for this
threshold value.
Let Y0(t) denote the number of type-0 cells still alive t time units into anti-cancer treatment, and
let Y1(t) denote the number of type-1 cells that have been produced through type-0 epimutations
up until time t. Since we are only interested in what happens during the initial stages of treatment,
and the type-1 population is assumed to be small compared to the initial type-0 population, we
ignore reversions from type-1 to type-0 and thus assume that the type-0 population decays at an
exponential rate |λ0|, with initial population size Y0(0) = n.
Note that given Y0(s) for 0 ≤ s ≤ t, the type-0 population produces a type-1 cell at rate µY0(s)
at time s. Therefore,
E[Y1(t)|Y0(s), s ≤ t] =
∫ t
0
µY0(s)ds,
from which we conclude
E[Y1(t)] =
∫ t
0
µne−|λ0|sds =
nµ
|λ0|(1− e
−|λ0|t).
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Note that E[Y1(t)]→ nµ/|λ0| as t→∞, so approximately
nµ/|λ0| (F.1)
type-1 cells are created during the initial stages of treatment, during which most of the type-0
population is eradicated.
Now let u  1. The number of type-1 cells, N1, needed to guarantee that the resistant popu-
lation survives with probability 1− u satisfies
1− (d1/r1)N1 ≥ 1− u,
where we use that d1/r1 is the extinction probability of a type-1 clone, assuming no reversions to
type-0 [47]. We therefore conclude that
N1 ≥ log u
log(d1/r1)
(F.2)
(recall that r1 > d1 by assumption). To determine the threshold epimutation rate µ
′ that guarantees
survival probability of at least 1− u under treatment, we combine (F.1) and (F.2) to get
µ′ ≈ |λ0| log u
n log(d1/r1)
. (F.3)
Appendix G Time to stable resistance
We are now interested in analyzing the time at which the first successful type-2 cell emerges in
the population during continuous anti-cancer therapy. Let Z0(s) and Z1(s) denote the number
of type-0 and type-1 cells alive at time s, now assuming the presence of permanent resistance
mechanisms (η > 0 and ξ0, ξ1 > 0). Assume the initial conditions (Z0(0), Z1(0)) = (n,m) and
that no permanently resistant (type-2) cell is present at the onset. Let ηeff be the ‘effective’
reprogramming rate, i.e. the rate at which epigenetic reprogramming produces a successful type-2
cell (a type-2 cell that gives rise to a clone that does not go extinct), and let ξeff0 and ξ
eff
1 be the
‘effective’ mutation rates. Then ηeff = ηλ2/r2, ξ
eff
0 = ξ0λ2/r2 and ξ
eff
1 = ξ1λ2/r2, since type-2 cells
form a single-type binary branching process with extinction probability d2/r2 = 1− λ2/r2 [47].
Let τ denote the time of first occurrence of a successful type-2 cell. Note that at any time s,
the total rate at which cells acquire a resistance-conferring mutation is r0ξ
eff
0 Z0(s) + r1ξ
eff
1 Z1(s),
and the total rate of epigenetic reprogramming is ηeffZ1(s). If we condition on the history of the
type-0 and type-1 population up until some time t, the number of type-2 cells that have emerged
by time t is then Poisson distributed with mean∫ t
0
(ξeff0 r0Z0(s) + ξ
eff
1 r1Z1(s) + η
effZ1(s))ds,
which implies that
P (τ > t | (Z0(s), Z1(s))s≤t)
= exp
(
−
∫ t
0
(ξeff0 r0Z0(s) + ξ
eff
1 r1Z1(s) + η
effZ1(s))ds
)
,
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since {τ > t} is the event that no type-2 cell has emerged by time t. Taking expectations, we arrive
at
P (τ > t)
= E
[
exp
(
−
∫ t
0
(ξeff0 r0Z0(s) + ξ
eff
1 r1Z1(s) + η
effZ1(s))ds
)]
.
We now argue that Z0(s) and Z1(s) in the exponent can be well-approximated by their means.
Assuming the initial condition (Z0(0), Z1(0)) = (n,m), we can write
(Z0(s), Z1(s)) =
n∑
j=1
(
Z
(0)
0,j (s), Z
(0)
1,j (s)
)
+
m∑
j=1
(
Z
(1)
0,j (s), Z
(1)
1,j (s)
)
,
where Z
(k)
i,j (t) represents the number of type-i cells present at time t descended from a single type-k
cell and {Z(k)i,j (t) : j ∈ {1, 2, . . .}} is an i.i.d. sequence of such random variables. Given sufficiently
large n and m, we know by the law of large numbers that the approximation (Z0(s), Z1(s)) ≈
(φ0(s), φ1(s)) should be justified. To examine fluctuations around the mean, we note that by the
central limit theorem,
n∑
j=1
(
Z
(0)
0,j (s), Z
(0)
1,j (s)
)
≈ n
(
E[Z
(0)
0,1 (s)], E[Z
(0)
1,1 (s)]
)
+
√
n
(
W1
√
Var
(
Z
(0)
0,1(s)
)
,W2
√
Var
(
Z
(0)
1,1(s)
))
,
where (W1,W2) is a mean-zero bivariate Gaussian. By equation (21) of Section V.7 of [39] we know
that there exists a C > 0 such that√
Var
(
Z
(0)
i,1 (s)
) ≤ CE[Z(0)i,1 (s)], s > 0.
We can therefore write
n∑
j=1
(
Z
(0)
0,j (s), Z
(0)
1,j (s)
)
≈ n
(
E[Z
(0)
0,1 (s)], E[Z
(0)
1,1 (s)]
)
(1 + C/
√
n).
A similar result holds for the descendants of the type-1 cells. Ignoring the second-order term, we
arrive at
P (τ > t)
≈ exp
(
−
∫ t
0
(ξeff0 r0φ0(s) + ξ
eff
1 r1φ1(s) + η
effφ1(s))ds
)
. (G.1)
To test the quality of this approximation, we show in Figure G.1 a comparison between (G.1) and
simulation results for as few as n = 104 starting cells. To calculate the mean number of type-0 and
type-1 cells alive at time s, φ0(s) and φ1(s) in (G.1), we can apply (3) in the main text. Technically,
the birth rates r0 and r1 should be replaced by r0(1− ξeff0 ) and r1(1− ξeff1 ), and the death rate d1
should be replaced by d1 + η
eff , to reflect the introduction of permanent resistance mechanisms,
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Figure G.1: Comparison of expression (G.1) (whole curves) with simulation results (dotted curves)
in the baseline parameter regime, assuming a starting population of n = 104 (bottom curve; left
axis), n = 105 (middle curve; left axis) or n = 106 cells (top curve; right axis). Simulation results
are based on 2000 runs of the process. Other parameter values are r0 = 0.04 (per hour), d0 = 0.08,
r1 = 0.0162, d1 = 0.015, µ = 4 · 10−5, ν = 4 · 10−4, η = 4 · 10−7, ξ0 = ξ1 = 10−7 (per cell division),
and m = 0.
but assuming ξ0, ξ1  1 and η  d1, we can safely ignore this minor complication. Using (3), we
can therefore calculate ∫ t
0
φ0(s)ds = −β
σ
(1− eσt)− α
ρ
(1− eρt),∫ t
0
φ1(s)ds = −γβ
σ
(1− eσt) + δα
ρ
(1− eρt),
(G.2)
which gives an explicit expression for (G.1) assuming σ 6= 0 and ρ 6= 0. Note that the expressions
in (G.2) can be interpreted as the ‘total mass’ of type-0 and type-1 cells, respectively, up until time
t.
In the main text, we apply (G.1) and (G.2) to evaluate interval treatment strategies, where
the anti-cancer agent is intermittently applied and removed. This can create a problem, since
our calculations of ηeff , ξeff0 and ξ
eff
1 assume that the rates r2 and d2 of birth and death of type-2
cells do not change over time. However, since we make the assumption in our baseline parameter
regime that r2 and d2 are identical on and off the anti-cancer agent, we do not have to make any
adjustments to (G.1) to use it to evaluate interval treatment strategies. In fact, since we assume
r2 = 0.04 and d2 = 0.0015 with λ2/d2 ≈ 1, we can effectively take ηeff = η, ξeff0 = ξ0 and ξeff1 = ξ1.
To determine whether stable resistance develops at all during continuous anti-cancer therapy,
we consider the event {τ = ∞}. It is possible to estimate its probability by taking t → ∞ in
(G.1), but then we first have to condition on whether the overall population of type-0 and type-1
cells goes extinct or not, since φ0(s) and φ1(s) blow up as s → ∞ for any supercritical process,
irrespective of the likelihood that the population survives. However, it is more straightforward to
proceed as follows. Let p0, p1 and p2 denote the extinction probabilities of clones started by a
single cell of each type. By conditioning on the initial event, we derive the following conditions for
these probabilities:
(r0 + d0 + µ) · p0 = r0(1− ξ0)p20 + d0 + µp1 + r0ξ0p0p2,
(r1 + d1 + ν + η) · p1 = r1(1− ξ1)p21 + d1 + νp0 + r1ξ1p1p2 + ηp2,
p2 = d2/r2,
(G.3)
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r0 d0 r1 d1 1− p0 1− p1 1− pn0pm1
0.04 0.08 0.01620.015 0.0049% 4.94% 100%
+10% 0.0055% 4.94% 100%
+10% 0.0041% 4.94% 100%
+10%+10% 0.0045% 4.94% 100%
+10% 0.0136% 13.58% 100%
+10% 0% 0% 0%
+10% +10% 0.0052% 5.16% 100%
+50% 0.0099% 4.94% 100%
+50% 0.0025% 4.94% 100%
+50%+50% 0.0033% 4.94% 100%
+50% 0.0366% 36.63% 100%
+50% 0% 0% 0%
+50% +50% 0.0058% 5.76% 100%
Table H.1: Response of the survival probability of (i) a clone started by a single type-0 cell (1−p0),
(ii) a clone started by a single type-1 cell (1−p1), and (iii) the overall population of n = 106 type-0
and m = 0 type-1 cells (1− pn0pm1 ), to changes in r0, r1, d0 and d1. The probabilities p0 and p1 can
be calculated using (C.1). In the top row, we show the baseline parameter values for r0, d0, r1 and
d1, and the survival probabilities given these values. In the remaining lines, we adjust one or two
parameters at a time as indicated and display survival probabilities given these changes. All rates
are measured per hour.
where we use that fact that type-2 cells form a single-type binary branching process with extinction
probability d2/r2. Note that these equations reduce to (C.1) if we set ξ0 = ξ1 = 0 and η = 0. We
can then calculate
P (τ =∞) = pn0pm1 , (G.4)
which gives the probability that stable resistance does not develop at all during continuous admin-
istration of anti-cancer treatment. The probability that stable resistance does develop is then
P (τ <∞) = 1− pn0pm1 . (G.5)
Appendix H Robustness analysis
Survival probability
Table H.1 shows how survival probability, both at the indidividual cell level and for the tumor
population as a whole, responds to changes in r0, d0, r1 and d1, pertinent to the discussion of
Section 4.1.
Threshold value for µ
Table H.2 shows how the threshold value for µ, denoted as µ′ and given by (11), responds to to
changes in r1 and d1, pertinent to the discussion of Section 4.2.
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r1 d1 µ
′
0.0162 0.015 3.59 · 10−6
+10% 1.60 · 10−6
+10% +∞
+10% +10% 3.59 · 10−6
+50% 0.57 · 10−6
+50% +∞
+50% +50% 3.59 · 10−6
Table H.2: Response of the threshold value µ′, as given by (11), to changes in r1 and d1. We use
+∞ to indicate that there is no value for µ for which tumor survival is guaranteed, which is the
case when the population is subcritical. All rates are measured per hour.
Evaluation of combination treatment strategies
We now discuss various possible changes to the assumptions underlying Figure 6 in the main text.
In this section, we let µd and νd denote the rates of epimutation and reversion when the epigenetic
drug is being applied to distinguish them from the rates µ and ν off the epigenetic drug.
Tumor size and rates of mutation and reprogramming
In the main text, we assume an initial population size of n = 106 · 0.999 and m = 106 · 0.001 cells,
an epigenetic reprogramming rate of η = 4 · 10−7 per hour, and a mutation rate of ξ0 = ξ1 = 10−7
per cell division. If we assume that the rate of epigenetic reprogramming is increased by an order of
magnitude to η = 4·10−6, the relative attractiveness of Schedule B over the other schedules becomes
even more pronounced than in the baseline case (Fig H.1a). If we also increase the mutation rate
an order of magnitude to ξ0 = ξ1 = 10
−6, it becomes more difficult to eradicate the tumor, but the
relative attractiveness of the schedules remains unchanged (Fig H.1b).
If we increase the population size one order of magnitude to n = 107 ·0.999 and m = 107 ·0.001,
assuming the baseline values η = 4 · 10−7 and ξ0 = ξ1 = 10−7 for the rates of reprogramming
and mutation (figure not shown), the effects will be similar to those shown in Figure H.1b, where
the population size is as in the baseline case but both rate parameters are increased an order of
magnitude. Thus, the relationship between initial population size and the rate of mutation and
epigenetic reprogramming is more important than the absolute value of each in isolation, and any
effect of increasing the population size can be negated by a proportional decrease in the these rates.
We also note that if the anti-cancer agent being applied reduces the birth rate r0 of type-0 cells, this
will have the same effect as reducing the mutation rate ξ0 (see discussion in Appendix A above).
For an even larger initial tumor size of n = 108 · 0.999 and m = 108 · 0.001, a resistance-
conferring mutation will be guaranteed to arise no matter which schedule is applied (figure not
shown), although we recover the same behavior as for the n = 107 · 0.999 and m = 107 · 0.001 case
if the change in size is accompanied by a smaller reprogramming rate, η = 4 · 10−8, and a smaller
mutation rate, ξ0 = ξ1 = 10
−8. However, even if the initial population size is n = 108 · 0.999 and
m = 108 · 0.001, with unchanged rates of mutation and reprogramming, there can still be benefits
to applying a combination of an anti-cancer agent and an epigenetic drug, since Schedule B can
prevent resistance conferred through epigenetic reprogramming (Fig H.1c). In fact, if we assume
that the epigenetic drug is stronger than in the main text, so that it increases the reversion rate ν
by three orders of magnitude and decreases the epimutation rate to the same extent, then Schedule
B is able to prevent resistance through epigenetic reprogramming with high probability, whereas
resistance is effectively guaranteed under any other schedule (Fig H.1d).
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Figure H.1: Time-evolution of the probability of successful type-2 emergence for the treatment
schedules examined in Figure 6 in the main text. Parameters behave as in Figure 6 except in
(a), η = 4 · 10−6 (per hour), in (b), η = 4 · 10−6 and ξ0 = ξ1 = 10−6 (per cell division), in (c),
n = 108 ·0.999, m = 108 ·0.001 and ξ0 = ξ1 = 0, in (d), n = 108 ·0.999, m = 108 ·0.001, ξ0 = ξ1 = 0,
µd = µ · 10−3 and νd = ν · 103, in (e), µd = µ · 10−1 and νd = ν · 101, and in (f), µd = µ · 10−3 and
νd = ν · 103.
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Different epigenetic drug action
In the main text, we assume that the epigenetic drug increases the reversion rate ν by two orders of
magnitude, and decreases the epimutation rate µ to the same extent. In Figures H.1e and H.1f, we
show results first assuming that the change in each is one order of magnitude (Fig H.1e), and then
three orders of magnitude (Fig H.1f). We note that Schedule B continues to be the most attractive
schedule, and in Figure H.1e, the difference between Schedule B and Schedules C,D becomes more
pronounced than for the case shown in the main text.
Faster or slower switching dynamics
In the main text, we assume an epimutation rate of µ = 4 · 10−5 in the absence of the epigenetic
drug, in accordance with our baseline parameter regime. In Figures H.2a and H.2b, we show results
assuming µ = 4 · 10−4 (Fig H.2a) and µ = 4 · 10−6 (Fig H.2b), with the epimutation rate µd in the
presence of the epigenetic drug obtained by reducing µ by two orders of magnitude in each case.
As before, the qualitative dynamics remain similar, with the difference between Schedule B and
the other schedules even more pronounced in Figure H.2a than for the baseline case.
Different treatment block sizes
In the main text, we assume that each treatment block is 2 days. In Figures H.2c and H.2d, we
show results assuming that each block is 1 day (Fig H.2c) or 3 days (Fig H.2d), and observe similar
results as before.
Resistant phenotype is not at a selective disadvantage off drug
In our baseline regime, we assume that the resistant type-1 phenotype is at a selective disadvantage
to drug-sensitive type-0 cells in the absence of the anti-cancer agent. Figure H.2e reveals that our
results do not depend on this assumption, as if we assume r1 = r0 = 0.04 and d1 = d0 = 0.0015 off
the anti-cancer agent, Schedule B continues to perform the best.
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Figure H.2: Time-evolution of the probability of successful type-2 emergence for the treatment
schedules examined in Figure 6 in the main text. Parameters behave as in Figure 6 except in (a),
µ = 4 ·10−4 in the absence of epigenetic drug, in (b), µ = 4 ·10−6 in the absence of epigenetic drug,
in (c), the size of each treatment block is 1 day as opposed to 2 days, in (d), the size of each block
is 3 days, and in (e), r1 = 0.04 (per hour) and d1 = 0.0015 in the absence of the anti-cancer agent.
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